Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus
I was diagnosed with lupus almost 16 years ago and it hasn’t been easy with the limited treatment options for lupus. So I was very excited for the news from Lupus Foundation of America about a new treatment that was approved by the FDA for lupus recently.
“Having another potential treatment option like Saphnelo is extremely exciting.”
It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this life-threatening autoimmune disease.
“After having only one therapy approved for lupus during the past 60 years, it is a cause for celebration to have two new treatment options approved in 2021 alone for this life-threatening autoimmune disease that affects an estimated 1.5 million Americans,” said Stevan W. Gibson, president and CEO, Lupus Foundation of America.
Saphnelo was developed by AstaZeneca. It will be use in treating adults with moderate SLE who are receiving moderate therapy
Lupus is an unpredictable and misunderstood autoimmune disease that affects different parts of the body. It is difficult to diagnose, hard to live with, and a challenge to treat. Lupus is a cruel mystery because it is hidden from view and difficult to describe, has a range of symptoms, strikes without warning, and has no known cause and no known cure. Its health effects can range from a skin rash to a heart attack. Lupus is debilitating and destructive and can be fatal, yet research on lupus remains underfunded relative to diseases of similar scope and devastation.
Lupus is an autoimmune disease that affects an estimated 1.5 million people.
For more information about Saphnelo & Lupus go to Lupus Foundation of America at lupus.org
SOURCE – Lupus Foundation of America
Disclaimer: This is not an endorsement of the drug “Saphnelo”.